|
Orthologous residues
|
|
BAD (human): S118‑p, BAD (mouse): S155‑p, BAD (rat): S156‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site, phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
phorbol ester
|
|
|
|
increase
|
|
|
isoproterenol
|
|
|
|
increase
|
|
|
IBMX, forskolin
|
|
|
|
increase
|
|
|
EGF
|
|
|
|
increase
|
|
|
|
|
PKACA (human)
|
|
increase
|
|
|
|
|
p90RSK (human)
|
|
increase
|
|
|
|
|
RSK2 (human)
|
|
increase
|
|
|
|
|
RSK3 (human)
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Effect of modification (process):
apoptosis, altered
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
Bcl-xL (human)
|
|
Disrupts
|
|
|
co-immunoprecipitation
|
|